How should blurred vision be managed in a patient with stage 4 metastatic giant‑cell carcinoma of the lung who has been taking osimertinib for two weeks?

Management of Blurred Vision in a Patient on Osimertinib

Blurred vision in this patient taking osimertinib for 2 weeks should prompt immediate ophthalmologic evaluation to assess for drug-related ocular toxicity, while continuing osimertinib unless vision-threatening complications are identified.

Immediate Assessment Required

The blurred vision requires urgent evaluation because osimertinib can cause several ocular adverse effects:

• Ophthalmologic examination is essential to identify the specific cause
• Key findings to assess: corneal changes, lens opacities, retinal vasculitis, or choroidal metastases
• Timeline consideration: At 2 weeks of therapy, this is an early presentation that warrants careful evaluation

Understanding Osimertinib-Related Ocular Effects

Known Ocular Toxicities from FDA Label

The FDA label 1 specifically documents lens fiber degeneration and lens opacities in animal studies at exposures comparable to human therapeutic doses. These findings showed:

• Progressive development over time (first noted at week 52 in rats)
• Gradual increase in incidence and severity with continued dosing
• Occurred at 0.2 times human exposure based on AUC

Documented Clinical Ocular Complications

While the provided evidence focuses primarily on osimertinib's efficacy for treating choroidal metastases 2, 3, 4, 5, one critical case report 6 describes bilateral hemorrhagic occlusive retinal vasculitis (HORV) developing 18 months after osimertinib initiation, presenting with:

• Blurry vision in both eyes
• Anterior chamber cells and vitreous cells
• Multiple retinal hemorrhages
• Severely non-perfused peripheral retinal areas

Management Algorithm

Step 1: Ophthalmologic Evaluation

Obtain comprehensive eye examination including:

• Visual acuity testing in both eyes
• Slit lamp examination for anterior chamber inflammation, lens changes
• Dilated fundus examination for retinal hemorrhages, vasculitis, or choroidal lesions
• Optical coherence tomography (OCT) if macular involvement suspected
• Fluorescein angiography if retinal vasculitis is suspected

Step 2: Determine Severity and Etiology

If vision-threatening complications identified (severe retinal vasculitis, significant macular edema):

• Consider dose reduction from 80 mg to 40 mg daily 6
• Initiate systemic corticosteroids (e.g., prednisolone 30 mg/day) 6
• Continue osimertinib at reduced dose given the critical importance of cancer control
• Close ophthalmologic monitoring

If mild, non-threatening changes (early lens changes, mild visual disturbance):

• Continue osimertinib at current dose
• Monitor closely with serial ophthalmologic examinations
• Document baseline for comparison

If choroidal metastasis identified:

• Continue osimertinib as it effectively treats choroidal metastases 2, 3, 4, 5
• Expect improvement within 1-3 months of therapy
• This represents therapeutic benefit, not toxicity

Step 3: Ongoing Monitoring

• Regular ophthalmologic follow-up throughout osimertinib therapy
• Do not discontinue osimertinib unless absolutely necessary for vision preservation, as this is first-line therapy for stage 4 EGFR-mutant NSCLC
• The case report 6 demonstrates successful management of severe HORV while maintaining osimertinib therapy through dose adjustment and corticosteroid use

Critical Considerations

Why Continue Osimertinib

Osimertinib should not be discontinued lightly because:

• It is the standard first-line therapy for EGFR-mutant advanced NSCLC 7, 8
• Median PFS is approximately 18-20 months 9, 10
• Median OS is approximately 42 months in real-world data 10
• CNS penetration is superior to other EGFR TKIs 7
• Early discontinuation compromises survival outcomes

Balancing Toxicity vs. Efficacy

The successful case management 6 demonstrates that even severe ocular toxicity (HORV) can be managed with:

• Dose reduction (80 mg to 40 mg daily)
• Systemic corticosteroids
• Local steroid treatment if needed
• Pan-retinal photocoagulation for ischemic areas
• Eventual dose re-escalation to 80 mg after stabilization

This patient maintained stable disease for 18 months after the ocular complication with visual acuity of 10/20 bilaterally 6.

Common Pitfalls to Avoid

1. Do not reflexively discontinue osimertinib for blurred vision without ophthalmologic assessment
2. Do not assume all visual symptoms are drug toxicity - choroidal metastases can present with blurred vision and respond to osimertinib 2, 3, 4
3. Do not delay ophthalmologic referral - early identification allows for appropriate intervention
4. Do not ignore the possibility of CNS metastases affecting vision - osimertinib has excellent CNS penetration and efficacy 7, 11

When to Consider Discontinuation

Discontinuation should only be considered if:

• Vision-threatening complications cannot be managed with dose reduction and supportive care
• Progressive visual loss despite intervention
• Patient preference after informed discussion of cancer control implications

In this specific case at 2 weeks of therapy, the most likely scenarios are either early drug-related changes (which may be manageable) or disease-related visual symptoms (which may improve with continued osimertinib). Immediate ophthalmologic evaluation will guide the appropriate management strategy while maintaining cancer control as the primary priority.